Clinical trials: Dementia Moderate, open to volunteers
Alzheimer Disease
The Safety and Efficacy of Sodium Pentaborate Pentahydrate in Patients With Mild to Moderate Alzheimer's Disease
Alzheimer's disease (AD) is the leading cause of dementia, affecting millions worldwide. With its global prevalence steadily increasing, particularly in low- and middle-income countries, the demand for effective treatments has…
- Trial name
- NCT06840054
- Testing
- Sodium Pentaborate Pentahydrate
- Volunteers
- 30 people
- Sponsor
- Tabriz University of Medical Sciences
Alzheimer's Disease
A Phase 2b/3 Clinical Study Evaluating T3D-959 in Mild-to-Moderate Alzheimer's Disease Subjects
This study is a Phase 2b/3 clinical trial of a new candidate drug (T3D-959) to treat patients with mild-to-moderate Alzheimer's.
- Trial name
- NCT06964230
- Testing
- T3D-959
- Where
- United States
- Volunteers
- 376 people
- Sponsor
- T3D Therapeutics, Inc.
Alzheimer Disease
A Study to Assess Safety and Tolerability and to Explore Efficacy of NSC001 in Mild to Moderate Alzheimer's Disease
The purpose of this study is to evaluate the safety and tolerability of NSC001 on in patients with mild to moderate Alzheimer's disease and to evaluate the influence of the compound on cognitive function.
- Trial name
- NCT06995573
- Testing
- NSC001
- Where
- 10 sites in Austria, Germany
- Volunteers
- 90 people
- Sponsor
- NSC-Therapeutics
Dementia
Exploratory Study of the Effects of Peptide PMS-001 on Long-Delay Recall in Patients With Moderate to Severe Dementia
This is a single-center, randomized, double-blind, placebo-controlled study. Patients will be randomly assigned to either the peptide intervention group (with dose escalation at 15mg, 30mg, 60mg, and 75mg) or the placebo control…
- Trial name
- NCT06946511
- Testing
- Peptide PMS-001 Intravenous Injection
- Where
- 2 sites in China
- Volunteers
- 50 people
- Sponsor
- Ruijin Hospital
Alzheimer Disease
Tricaprilin Phase 3 ALTER-AD (Alternative-Alzheimer Disease) Study
The purpose of this study is to evaluate the effects of tricaprilin (20 g twice a day) on cognition, global function, activities of daily living, resource utilisation, safety, and tolerability, in participants with mild to…
- Trial name
- ALTER-AD (NCT05809908)
- Testing
- Tricaprilin
- Volunteers
- 535 people
- Sponsor
- Cerecin
Alzheimer's Disease
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC for cognitive impairment in Alzheimer's Disease
- Trial name
- MINDSET 2 (NCT06976203)
- Testing
- KarXT, KarX-EC
- Where
- 128 sites in United States, Argentina and 15 more
- Volunteers
- 586 people
- Sponsor
- Bristol-Myers Squibb
Alzheimer's Disease, Lewy Body Dementia
Pulsed Electromagnetic Field Treatment With Dementia Patients
An open label pilot study in mild to moderate AD/ADRD patients to assess the effects of treatment with ECHS AD/ADRD pulsed electromagnetic treatment device on disease progression. Enrolled patients will receive active devices.
- Conditions
- Alzheimer's Disease, Lewy Body Dementia, Vascular Dementia
- Trial name
- NCT06862557
- Testing
- ECHS AD Device
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Herrick Medical LLC
Moderate to Severe Alzheimer's Disease
GV1001 Subcutaneous for the Treatment of Moderate to Severe Alzheimer's Disease(AD)
The objective of this study is to evaluate the safety and efficacy of GV1001 administered subcutaneously in patients with moderate to severe Alzheimer's disease (AD).
- Trial name
- NCT05303701
- Testing
- GV1001 1.12mg
- Volunteers
- 750 people
- Sponsor
- Samsung Pharmaceutical Co., Ltd.
Alzheimer Disease (AD)
Study of Neural Stem Cell-Derived Exosomes in Moderate-to-Severe Early-Onset Alzheimer's Disease
This is an open-label, single-center, phase I clinical study in patients with moderate-to-severe early-onset Alzheimer's disease.
- Trial name
- NCT07554872
- Testing
- Neural Stem Cell-Derived Exosomes
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Shanghai Mental Health Center
Alzheimer's Disease, Blood Brain Barrier
Pilot Clinical Trial to Assess the Safety of NMS-01 in Patients With Mild to Moderate Alzheimer's Disease
A single-center, single-arm, prospective, open-label, pilot clinical trial to evaluate the safety and efficacy of the Focused ultrasound stimulator system (NMS-01) for transient Blood-Brain Barrier (BBB) opening in patients with…
- Trial name
- NMSBBBOYUSH01 (NCT07869238)
- Testing
- NMS-01
- Where
- South Korea
- Volunteers
- 10 people
- Sponsor
- Neumous Inc.
Alzheimer Disease, Lewy Body Dementia (LBD)
Deep Cervical Lymphaticovenous Anastomosis Surgery for Moderate-to-Advanced Dementia Patients
This clinical trial aims to evaluate the clinical efficacy and safety of Deep Cervical Lymphaticovenous Anastomosis (DLVA) in patients aged 50-80 with moderate to severe neurodegenerative dementia.
- Conditions
- Alzheimer Disease, Lewy Body Dementia (LBD), Frontotemporal Dementia (FTD), Dementia
- Trial name
- NCT06978946
- Testing
- Deep Cervical Lymphaticovenous Anastomosis(DLVA)
- Where
- China
- Volunteers
- 85 people
- Sponsor
- RenJi Hospital
Alzheimer Disease, Mild Cognitive Impairment
A Study of NTRX-07 in Participants With Alzheimer's Disease
1. Study Overview NeuroTherapia Inc. is conducting a clinical study to explore the safety and effects of a new drug called NTRX- 07.
- Trial name
- SPPN-AD (NCT07058688)
- Testing
- NTRX-07
- Where
- 6 sites in Czechia, Hungary and 1 more
- Volunteers
- 48 people
- Sponsor
- NeuroTherapia, Inc.
Alzheimer's Disease
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC for cognitive impairment in Alzheimer's Disease
- Trial name
- MINDSET 1 (NCT06976216)
- Testing
- KarXT, KarX-EC
- Where
- 119 sites in United States, Argentina and 17 more
- Volunteers
- 586 people
- Sponsor
- Bristol-Myers Squibb
Dementia
Dyadic Personalized Home-Based Activity Program for Mild-to-Moderate Dementia Patients Post-Discharge
This interventional study aims to evaluate the efficacy of a dyadic personalized home-based activity program in managing behavioral and psychological symptoms of dementia (BPSD) among home-dwelling people living with…
- Trial name
- NCT07081750
- Testing
- Dyadic personalized home-based activity program intervention, Routine care
- Where
- China
- Volunteers
- 55 people
- Sponsor
- Fujian Medical University
Dementia
CST+MST Intervention on People Living With Mild-to-moderate Dementia
Non-pharmacological interventions such as Cognitive Stimulation Therapy (CST) and physical activity are recommended for people living with mild-to-moderate dementia.
- Trial name
- CST+MST (NCT07625241)
- Testing
- Cognitive Stimulation Therapy and Motor Stimulation Treatment
- Where
- Italy
- Volunteers
- 421 people
- Sponsor
- Istituto Superiore di Sanità
Alzheimer's Disease
Evaluation of NBI-1117567 in Participants With Mild to Moderate Alzheimer's Disease (AD) Taking a Background Acetylcholinesterase Inhibitor
This study is designed to evaluate the efficacy on improving cognitive performance as well as the safety, tolerability, and pharmacokinetics (PK) of NBI-1117567 administered once daily (QD) in adults with mild to moderate AD who…
- Trial name
- NCT07832383
- Testing
- NBI-1117567
- Volunteers
- 135 people
- Sponsor
- Neurocrine Biosciences
Alzheimer Disease
Allogeneic Adipose Tissue Derived-stem Cells in Alzheimer Disease
A3D is a phase I/II clinical trial. The primary objective is to evaluate the safety of allogeneic adipose tissue derived-stem cells (AdMSC) administered by intravenous (IV) route in mild to moderate Alzheimer disease (AD) using a…
- Trial name
- A3D (NCT07367815)
- Testing
- CellREADY® drug product IV dose of 50 millions, CellREADY® drug product IV dose of 100 millions, cerebral RMI
- Where
- France
- Volunteers
- 9 people
- Sponsor
- University Hospital, Toulouse
Alzheimer's Dementia
Phase 3 Clinical Trial of Wujia Yizhi Granules in the Treatment of Mild-to-moderate Alzheimer's Dementia (Syndrome of Deficiency of Spleen and Kidney)
This study is a randomized, double-blind, placebo-controlled phase 3 design aimed at further verifying the safety and efficacy of Wujia Yizhi granules for mild-to-moderate Alzheimer's dementia
- Trial name
- NCT06534723
- Testing
- Wujia Yizhi granules
- Where
- China
- Volunteers
- 570 people
- Sponsor
- Sichuan Jishengtang Pharmaceutical Co., Ltd.
Mild Traumatic Brain Injury, Moderate Traumatic Brain Injury
Contributions of mTBI to Neurodegeneration Due to Chronic Traumatic Encephalopathy (CTE) and Alzheimer's Disease (AD)
This is a research study that aims to examine whether Veterans with mild Traumatic Brain Injuries are at risk for dementia by studying their memory, brain wave activity, brain structure and proteins that can be elevated after…
- Conditions
- Mild Traumatic Brain Injury, Moderate Traumatic Brain Injury, Mild Cognitive Impairment
- Trial name
- NCT04124029
- Testing
- No Intervention is used for this study but all subjects will be asked to complete electroencephalogram (EEG) testing and an MRI scan., No intervention is used for this study but all subjects will be asked to complete a venous blood draw procedure and a lumbar puncture procedure.
- Where
- United States
- Volunteers
- 800 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Primary Progressive Aphasia
Semantic Rehabilitation for Patients With Primary Progressive Semantic Aphasia
This project aims to measure the effect of a semantic rehabilitation protocol for patients with primary progressive semantic aphasia and using the SCED methodology.
- Trial name
- SCED-APPvs (NCT04957537)
- Testing
- semantic therapy and semantic re-education
- Where
- France
- Volunteers
- 15 people
- Sponsor
- University Hospital, Toulouse